Recruiting

Eye drop strategies to protect vision during ovarian cancer treatment

Plain-English translation of NCT06365853 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new cancer medicine called for people with recurrent ovarian cancer. The study is specifically designed to find the best way to protect your eyes while receiving this treatment, by comparing two different types of preventive eye drops that you would use alongside the medication.

The new treatment can sometimes cause eye problems as a side effect. Researchers want to find out which eye drop strategy—steroid drops or vasoconstricting drops—works best to prevent or reduce these vision-related side effects.

Do you qualify?

You likely qualify if…

you have been diagnosed with recurrent ovarian, fallopian tube, or peritoneal cancer that is folate receptor-alpha positive (determined by a specific lab test)
your cancer has high folate receptor-alpha expression as confirmed by the VENTANA test
if you have a BRCA mutation, you have already received PARP inhibitor therapy
you have finished your previous cancer treatment at least 4 weeks ago (or 5 half-lives, whichever is shorter)
you have recovered from side effects of previous treatments to Grade 1 or your baseline level
if you can become pregnant, you are willing to use effective birth control during treatment and for at least 7 months after your last dose

You likely don't qualify if…

you have active eye problems or corneal disease, including uncontrolled glaucoma, diabetic retinopathy, or a history of corneal transplant
you have significant vision problems, such as vision worse than 20/70 in either eye or vision in only one eye
you have Grade 2 or higher nerve damage (peripheral neuropathy) from previous treatments
you are already taking steroid or vasoconstricting eye drops, or have taken them within the past 5 weeks
you have received mirvetuximab soravtansine or other folate receptor-alpha targeting treatments before

What participation looks like

You would be randomly assigned to use one of two eye drop regimens alongside your cancer medication, which is given as an infusion every 3 weeks. One group uses steroid eye drops starting one day before treatment and continuing for several days; the other uses vasoconstricting drops starting on the day of treatment. Both groups also use lubricating drops throughout each 21-day cycle. You will have regular eye exams and monitoring to track any vision changes and ensure the eye drop strategy is working well for you.

AI-generated summary from trial data · Jun 15, 2026 · Not medical advice

Eye drop strategies to protect vision during ovarian cancer treatment

What is this trial?

Do you qualify?

What participation looks like

Trial locations